Outcome predictors for intestinal Behçet's disease

Yonsei Medical Journal

Volumn 54, Issue 5, 2013, Pages 1084-1090

  Park, Jae Jun ^a   Kim, Won Ho ^b   Cheon, Jae Hee ^b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Intestinal Beh et's disease; Medical treatment; Prognostic factors; Surgical treatment

Indexed keywords

AZATHIOPRINE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; PREDNISOLONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA;

BEHCET DISEASE; DISEASE ACTIVITY; DRUG DOSE REDUCTION; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; INTESTINE INJURY; INTESTINE PERFORATION; LAPAROTOMY; OUTCOME ASSESSMENT; RELAPSE; REMISSION; REVIEW; STOMACH ULCER;

INTESTINAL BEHÇET'S DISEASE; MEDICAL TREATMENT; PROGNOSTIC FACTORS; SURGICAL TREATMENT;

ADRENAL CORTEX HORMONES; ADULT; AGE FACTORS; BEHCET SYNDROME; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; INTESTINAL DISEASES; MALE; PROGNOSIS; SEX FACTORS;

EID: 84880979493     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2013.54.5.1084     Document Type: Review

References (42)

1. Kobayashi K, Ueno F, Bito S, Iwao Y, Fukushima T, Hiwatashi N, et al. Development of consensus statements for the diagnosis and management of intestinal Behçet's disease using a modified Del-phi approach. J Gastroenterol 2007;42:737-45.
2. Sakane T, Takeno M, Suzuki N, Inaba G. Behçet's disease. N Engl J Med 1999;341:1284-91.
3. Suzuki Kurokawa M, Suzuki N. Behçet's disease. Clin Exp Med 2004;4:10-20.
4. Dilsen N. History and development of Behçet's disease. Rev Rhum Engl Ed 1996;63:512-9.
5. Kaklamani VG, Vaiopoulos G, Kaklamanis PG. Behçet's Disease. Semin Arthritis Rheum 1998;27:197-217.
6. Bayraktar Y, Ozaslan E, Van Thiel DH. Gastrointestinal manifestations of Behçet's disease. J Clin Gastroenterol 2000;30:144-54.
7. Cheon JH, Celik AF, Kim WH. Behçet's disease: gastrointestinal involvement. In: Yazici Y, Yazici H, editors. Behçet's syndrome. New York: Springer; 2010. p.165-88.
8. Shimizu T, Ehrlich GE, Inaba G, Hayashi K. Behçet disease (Behçet syndrome). Semin Arthritis Rheum 1979;8:223-60.
9. Lakhanpal S, Tani K, Lie JT, Katoh K, Ishigatsubo Y, Ohokubo T. Pathologic features of Behçet's syndrome: a review of Japanese autopsy registry data. Hum Pathol 1985;16:790-5.
10. Gürler A, Boyvat A, Türsen U. Clinical manifestations of Behçet's disease: an analysis of 2147 patients. Yonsei Med J 1997;38:423-7.
11. Lee CR, Kim WH, Cho YS, Kim MH, Kim JH, Park IS, et al. Colonoscopic findings in intestinal Behçet's disease. Inflamm Bowel Dis 2001;7:243-9.
12. Mizushima Y, Inaba G, Himura Y, Ohno S. Diagnostic criteria for Behçet's disease in 1987, and guideline for treating Behçet's disease. Saishin Igaku 1988;43:391-3.
13. Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease. Lancet 1990;335:1078-80.
14. Shin SJ, Lee SK, Kim TI, Cheon JH, Kim ES, Kim BC, et al. Chronological changes in the systemic manifestations of intestinal Behçet's disease and their significance in diagnosis. Int J Colorectal Dis 2010;25:1371-6.
15. Cheon JH, Kim ES, Shin SJ, Kim TI, Lee KM, Kim SW, et al. Development and validation of novel diagnostic criteria for intestinal Behçet's disease in Korean patients with ileocolonic ulcers. Am J Gastroenterol 2009;104:2492-9.
16. Ebert EC. Gastrointestinal manifestations of Behçet's disease. Dig Dis Sci 2009;54:201-7.
17. Jung YS, Cheon JH, Park SJ, Hong SP, Kim TI, Kim WH. Clinical course of intestinal Behçet's disease during the first five years. Dig Dis Sci 2013;58:496-503.
18. Jung YS, Yoon JY, Hong SP, Kim TI, Kim WH, Cheon JH. Influence of age at diagnosis and sex on clinical course and long-term prognosis of intestinal Behçet's disease. Inflamm Bowel Dis 2012;18:1064-71.
19. Kim DK, Yang SK, Byeon JS, Myung SJ, Jo JY, Choi KD, et al. Clinical manifestations and course of intestinal Behçet's disease: an analysis in relation to diaesase subtypes. Intest Res 2005;3:48-54.
20. Choi IJ, Kim JS, Cha SD, Jung HC, Park JG, Song IS, et al. Longterm clinical course and prognostic factors in intestinal Behçet's disease. Dis Colon Rectum 2000;43:692-700.
21. Chung MJ, Cheon JH, Kim SU, Park JJ, Kim TI, Kim NK, et al. Response rates to medical treatments and long-term clinical outcomes of nonsurgical patients with intestinal Behçet disease. J Clin Gastroenterol 2010;44:e116-22.
22. Kim JS, Lim SH, Choi IJ, Moon H, Jung HC, Song IS, et al. Prediction of the clinical course of Behçet's colitis according to macroscopic classification by colonoscopy. Endoscopy 2000;32:635-40.
23. Yim SM, Kim DH, Lee HJ, Jang HW, Park SJ, Hong SP, et al. Mucosal healing predicts the long term prognosis of intestinal Behçet's Disease. Intest Res 2013;11(Suppl1):43.
24. Pineton de Chambrun G, Peyrin-Biroulet L, Lémann M, Colombel JF. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 2010;7:15-29.
25. Choi CH, Kim TI, Kim BC, Shin SJ, Lee SK, Kim WH, et al. Anti-Saccharomyces cerevisiae antibody in intestinal Behçet's disease patients: relation to clinical course. Dis Colon Rectum 2006; 49:1849-59.
26. Naganuma M, Iwao Y, Inoue N, Hisamatsu T, Imaeda H, Ishii H, et al. Analysis of clinical course and long-term prognosis of surgical and nonsurgical patients with intestinal Behçet's disease. Am J Gastroenterol 2000;95:2848-51.
27. Shin SJ, Kim BC, Kim TI, Lee SK, Lee KH, Kim WH. Anti-alpha-enolase antibody as a serologic marker and its correlation with disease severity in intestinal Behçet's disease. Dig Dis Sci 2011;56:812-8.
28. Jung YS, Hong SP, Kim TI, Kim WH, Cheon JH. Long-term clinical outcomes and factors predictive of relapse after 5-amino-salicylate or sulfasalazine therapy in patients with intestinal Behcet disease. J Clin Gastroenterol 2012;46:e38-45.
29. Park JJ, Cheon JH, Moon CM, Lee JH, Jeon SM, Bok HJ, et al. Long-term clinical outcomes after the first course of corticosteroid therapy in patients with moderate to severe intestinal Behget's disease. Gastroenterology 2010;138(Suppl1):S698-9.
30. Jung YS, Cheon JH, Hong SP, Kim TI, Kim WH. Clinical out-comes and prognostic factors for thiopurine maintenance therapy in patients with intestinal Behcet's disease. Inflamm Bowel Dis 2012;18:750-7.
31. Yamashita N, Kaneoka H, Kaneko S, Takeno M, Oneda K, Koizumi H, et al. Role of gammadelta T lymphocytes in the development of Behçet's disease. Clin Exp Immunol 1997;107:241-7.
32. Hassard PV, Binder SW, Nelson V, Vasiliauskas EA. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report. Gastroenterology 2001;120:995-9.
33. Travis SP, Czajkowski M, McGovern DP, Watson RG, Bell AL. Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody. Gut 2001;49:725-8.
34. Kram MT, May LD, Goodman S, Molinas S. Behçet's ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case. Dis Colon Rectum 2003;46: 118-21.
35. Mussack T, Landauer N, Ladurner R, Schiemann U, Goetzberger M, Burchardi C, et al. Successful treatment of cervical esophageal perforation in Behcet's disease with drainage operation and infliximab. Am J Gastroenterol 2003;98:703-4.
36. Byeon JS, Choi EK, Heo NY, Hong SC, Myung SJ, Yang SK, et al. Antitumor necrosis factor-alpha therapy for early postoperative recurrence of gastrointestinal Behçet's disease: report of a case. Dis Colon Rectum 2007;50:672-6.
37. Ju JH, Kwok SK, Seo SH, Yoon CH, Kim HY, Park SH. Successful treatment of life-threatening intestinal ulcer in Behçet's disease with infliximab: rapid healing of Behçet's ulcer with infliximab. Clin Rheumatol 2007;26:1383-5.
38. Naganuma M, Sakuraba A, Hisamatsu T, Ochiai H, Hasegawa H, Ogata H, et al. Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet's disease. Inflamm Bowel Dis 2008;14:1259-64.
39. Iwata S, Saito K, Yamaoka K, Tsujimura S, Nawata M, Hanami K, et al. Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet's disease. Mod Rheumatol 2011;21:184-91.
40. Lee JH, Cheon JH, Jeon SW, Ye BD, Yang SK, Kim YH, et al. Efficacy of Infliximab in Intestinal Behçet's Disease: A Korean Multicenter Retrospective Study. Inflamm Bowel Dis 2013. [Epub ahead of print]
41. Moon CM, Cheon JH, Shin JK, Jeon SM, Bok HJ, Lee JH, et al. Prediction of free bowel perforation in patients with intestinal Behçet's disease using clinical and colonoscopic findings. Dig Dis Sci 2010;55:2904-11.
42. Jung YS, Yoon JY, Lee JH, Jeon SM, Hong SP, Kim TI, et al. Prognostic factors and long-term clinical outcomes for surgical patients with intestinal Behcet's disease. Inflamm Bowel Dis 2011;17:1594-602.